KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Depreciation and Depletion (2016 - 2025)

Charles River Laboratories International (CRL) has 15 years of Depreciation and Depletion data on record, last reported at $45.1 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 6.82% year-over-year to $45.1 million; the TTM value through Dec 2025 reached $177.6 million, down 6.62%, while the annual FY2025 figure was $177.6 million, 6.62% down from the prior year.
  • Depreciation and Depletion reached $45.1 million in Q4 2025 per CRL's latest filing, up from $44.8 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $155.6 million in Q4 2022 and bottomed at $559000.0 in Q1 2022.
  • Average Depreciation and Depletion over 5 years is $42.1 million, with a median of $44.4 million recorded in 2023.
  • The widest YoY moves for Depreciation and Depletion: up 7878.53% in 2023, down 70.12% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $138.6 million in 2021, then increased by 12.28% to $155.6 million in 2022, then tumbled by 70.12% to $46.5 million in 2023, then rose by 4.09% to $48.4 million in 2024, then fell by 6.82% to $45.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $45.1 million in Q4 2025, $44.8 million in Q3 2025, and $44.3 million in Q2 2025.